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Long term disease free survival 
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Abstract 
Background: Small cell bladder cancer (SCBC) is an aggressive subtype accounting for less than 1 % of all bladder 
malignancies associated with rapid progression, early metastases formation and high mortality rates.
Case presentation: We present an unusual long term disease free survival of a 60 year-old man who was diagnosed 
with SCBC two and a half years ago. He underwent four cycles of cisplatin/etoposide chemotherapy as well as a 
prophylactic whole-brain radiotherapy followed by a radical cystoprostatectomy and ileal neobladder with extended 
pelvic lymphadenectomy. Since 33 months the patient is now recurrence-free.
Conclusion: In this case report, we were able to show that early multimodal therapy results in long term disease free 
survival, thus we highly recommend neoadjuvant chemotherapy as a part of multimodal management of a primary 
metastases-free, localized and surgically resectable SCBC.
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Background
Bladder cancer is one of the most common urological 
malignancies in men and women. While about 95  % of 
diagnosed bladder cancers are histologically urothelial 
cancers, small cell bladder cancer (SCBC) is an aggressive 
subtype accounting for less than 1 % of all bladder malig-
nancies associated with rapid progression, early metasta-
ses formation and high mortality rates [1–3].
SCBC primarily affects caucasian males between 60 
and 80  years, mostly with a history of heavy smoking. 
Clinical symptoms like hematuria, imaging and cystos-
copy do not allow the prediction of this aggressive type 
of bladder cancer, thus only tissue diagnostics are able to 
diagnose SCBC. In the recent years, new histopathologi-
cal markers including TMPSS-ERG fusions or a positive 
HPV status have been reported as risk factors for SCBC 
[4, 5].
As no general guidelines for the optimal treatment of 
SCBC are available in the urological field, single modal-
ity local therapy (15 %), surgical (21 %) or radiation-based 
(14 %) as well as multimodal therapies (50 %) including 
cisplatin-based chemotherapeutic regimes have been 
reported [5]. A recent investigation utilizing the National 
Cancer Data Base based on 960 SCBC patients revealed 
that median overall survival (OS) in patients who were 
metastasis free at primary diagnosis was 8.3 months [6].
We present an unusual long term disease free survival 
of a 60 year old man who was diagnosed with SCBC two 
and a half years ago. He underwent four cycles of cispl-
atin/etoposide chemotherapy as well as a prophylactic 
whole brain radiotherapy (WBRT) followed by a radical 
cystoprostatectomy and ileal neobladder with extended 
pelvic lymphadenectomy. Currently, the patient is recur-
rence-free since 33 months.
Case report
A 60 years-old man was referred to our department due 
to painless gross hematuria. The patient had no risk fac-
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occupational risk factors or hereditary factors. In addi-
tion, no other pre-existing conditions were known. The 
patient was painless and did not have any B-symptoms 
including weight loss or night sweats, furthermore, no 
neurological deficits were reported.
After exclusion of urinary infection as cause for hema-
turia, cystoscopy has been performed revealing a 6  cm 
solid tumor on the right bladder wall. Urinary cytology 
(voided urine and bladder washing) remained negative.
Consequently, a transurethral resection of the tumor 
has been performed and the tumor was macroscopically 
totally removed. Primary histology of the tumor speci-
men showed a muscle invasive small cell neuroendocrine 
carcinoma pT2a GIII. Moreover, tumor cells were posi-
tive for synaptophysin and AE1/AE3, with a high pro-
liferation rate (KI-67) of 95 % on immunohistochemical 
analysis (Fig.  1). In contrast, chromogranin A, CD56, 
CD3, CD20, TdT, S-100 and HMB45 confirmed negative 
staining.
18 FDG-positron emission tomography/computed 
tomography (PET/CT) performed at the time of pri-
mary diagnosis did not show any lymph node or visceral 
metastatic tumor spread. A subsequent cranial magnet 
resonance tomography (MRT) also confirmed no tumor 
infiltration into the brain.
As there are reports of increased survival rates upon 
neoadjuvant chemotherapy in patients suffering from 
SCBC [5], the patient underwent four cycles (day 1–3; 
1 cycle  =  21  days) of cisplatin (25  mg/m2)/etoposide 
(100  mg/m2) without any complications. In addition, 
we performed a prophylactic WBRT with a total dose 
of 26 Gray. Subsequently, the patient underwent radi-
cal cystoprostatectomy and ileal neobladder with bilat-
eral extended pelvic lymphadenectomy (including 32 
resected tumor-free lymph nodes). Final pathology con-
firmed complete response to neoadjuvant chemotherapy, 
with no vital small cell carcinoma tissue formations in 
both the lymph nodes and the cystoprostatectomy speci-
men (ypT0, N0, L0, V0, Pn0). An uneventful intra- and 
postoperative course was observed. The time from tran-
surethral resection to chemotherapy start was 28  days. 
34  days after chemotherapy was stopped, radical cysto-
prostatectomy has been performed.
Currently, the patient undergoes 6-monthly regular 
follow-up controls including urinary cytology (voided 
urine), measurement of residual urine, blood gas analysis 
Fig. 1 Hematoxylin and eosin staining of cancer tissue sections (a) and immunohistochemistry for KI-67 (b), synaptophysin (c) and AE1/AE3 (d)
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and imaging studies (chest/abdominal CT scan every 
second visit or chest radiography in combination with 
abdominal ultrasound). We noticed no evidence for 
relapse, even 33 months after initial diagnosis of SCBC.
Discussion
SCBC is a rare urological disease consequently associated 
with obvious limitations in literature and treatment expe-
rience leading to the fact that no clear urological-guide-
line based standard treatment is available for patients 
suffering from SCBC. To our knowledge, only the Cana-
dian Association of Genitourinary Medical Oncologists 
recommended in 2013 treating the disease with neoadju-
vant (Level 3, Grade C) or adjuvant chemotherapy (Level 
4, Grade D) using cisplatin and etoposide (Level 3, Grade 
C), followed by cystectomy or radiation in a bladder-
sparing therapy (Level 3, Grade C) [7].
Focusing on the literature, a multimodal treatment 
combining cisplatin-based neoadjuvant chemother-
apy with radical surgery seems to be most efficacious, 
whereof chemotherapy has the key role in this therapy 
concept [8]. However, also bladder preservation mul-
timodality approaches with a maximal complete tran-
surethral resection, followed by radiation therapy and 
concurrent chemotherapy has demonstrated promising 
oncological outcomes [9]. Despite of this evidence, in the 
present case we decided to undergo radical cystoprosta-
tectomy as the primary tumor has a size of 6 cm infiltrat-
ing almost the whole right bladder side-wall.
In addition, our patient underwent prophylactic whole-
brain radiation as it has been reported that it may be 
considered and discussed with patients with limited and 
extensive disease who have had a good clinical response 
to treatment [7].
In general, the concept of neoadjuvant chemotherapy 
even if radiography lacks the evidence of metastatic 
disease, underlines the possibility to treat micrometa-
static disease at an early stage and downstage the disease 
thereby facilitating radical surgery. In addition, as espe-
cially cisplatin correlates with numerous side effects, tol-
erability is higher before than after surgery.
Already 12 years ago Siefker-Radtke et al. [10] compared 
retrospectively the efficacy of neoadjuvant chemotherapy 
to surgery alone in a cohort of 46 patients. Thereby they 
found that the five years cancer specific survival was sig-
nificantly higher in the chemotherapy group compared to 
those patients who underwent immediate surgery alone. 
A consequently performed prospective phase II clinical 
trial by the same group including 30 patients confirmed 
the survival benefit of neoadjuvant chemotherapy as part 
of multimodal treatment in SCBC [11].
In addition, there is evidence that neoadjuvant chemo-
therapy leads to pathological downstaging to ≤pT1N0 in 
62 % of tumors compared to 9 % of patients treated with 
surgery alone. Our data are in line, or even better as these 
data, as pathology of the cystoprostatectomy specimen 
showed complete response, without any evidence for 
residual tumor after four neoadjuvant cycles of cisplatin/
etoposide [12].
In general, SCBC primarily affects males aged between 
60–80  years with a history of heavy smoking (reviewed 
in [13]). Interestingly, the present patient did not report 
a history of smoking, indicating that other risk factors 
induce genetic aberrations, mutations or epigenetic alter-
ations. Thus, we feel the importance of further studies 
investigating this issue.
Reviewing the literature, median overall survival in 
patients who were metastasis-free at primary diagnosis 
was 8.3 months [5]. The patient presented in the manu-
script has currently a disease-free OS of 33 months.
However, one has to consider that our case harbored an 
initial T2 GIII stage, with a complete response (pT0 N0) 
after neoadjuvant chemotherapy underlying the impor-
tance of a multimodal treatment concept. This might be 
of importance as Choong et al. [14] showed that higher 
stages are associated with poor outcome. On the other 
hand, our patient had a large tumor (6 cm) and—in line 
with urothelial cancers of the bladder tumor size >3 cm 
may be classified as a high risk tumor. Again, the fact that 
the patient had no smoking history possibly influences 
this extraordinary satisfactory outcome.
However, in summary we can assume that early multi-
modal treatment may help to diminish recurrence or pro-
gression rates in patients with SCBC.
Conclusion
SCBC is a rare and very aggressive disease with a median 
overall survival rate of 8.3 months. Multimodal treatment 
has been shown to be superior to local therapy alone. 
Early multimodal therapy may result in long term disease 
free survival, thus we highly recommend neoadjuvant 
chemotherapy as a part of multimodal management of a 
primary metastases-free, localized and surgically resect-
able SCBC.
Abbreviations
OS: overall survival; PET/CT: positron emission tomography/computed tomog-
raphy; MRT: magnet resonance tomography; SCBC: small cell bladder cancer; 
WBRT: whole brain radiotherapy.
Authors’ contributions
IH, RP, GT manuscript. GS pathology. WH supervision, surgery. All authors read 
and approved the final manuscript.
Author details
1 Department of Urology, Medical University Innsbruck, Anichstrasse 35, 
6020 Innsbruck, Austria. 2 Division of General Pathology, Department 
of Pathology, Medical University Innsbruck, Innsbruck, Austria. 
Page 4 of 4Heidegger et al. Eur J Med Res  (2016) 21:40 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Competing interests
The authors declare that they have no competing interests.
Received: 4 August 2016   Accepted: 6 October 2016
References
 1. Blomjous CE, Vos W, De Voogt HJ, et al. Small cell carcinoma of the urinary 
bladder. A clinicopathologic, morphometric, immunohistochemical, and 
ultrastructural study of 18 cases. Cancer. 1989;64:1347–57.
 2. Lopez JI, Angulo JC, Flores N, Toledo JD. Small cell carcinoma of the 
urinary bladder. A clinicopathological study of six cases. Br J Urol. 
1994;73:43–9.
 3. Mazzucchelli R, Scarpelli M, Galosi AB, Lopez-Beltran A, Cheng L, Mon-
tironi R. “Pathology of the Bladder” (Capitolo di Libro Internazionale), 
p. 26–39, October 2015, in Advances in Bladder Cancer Management, 
Copyright © 2015 Future Medicine Ltd, doi: 10.2217/9781780844237, 
eISBN (PDF): 978-1-78084-423.
 4. Williamson SR, Zhang S, Yao JL, et al. ERG-TMPRSS2 rearrangement is 
shared by concurrent prostatic adenocarcinoma and prostatic small cell 
carcinoma and absent in small cell carcinoma of the urinary bladder: 
evidence supporting monoclonal origin. Mod Pathol. 2011;24(8):1120–7.
 5. Wang X, Zhang S, MacLennan GT, et al. Epidermal growth factor receptor 
protein expression and gene amplification in small cell carcinoma of the 
urinary bladder. Clin Cancer Res. 2007;13(3):953–7.
 6. Geynisman DM, Handorf E, Wong YN, et al. Advanced small cell carci-
noma of the bladder: clinical characteristics, treatment patterns and 
outcomes in 960 patients and comparison with urothelial carcinoma. 
Cancer Med. 2016;5(2):192–9. doi:10.1002/cam4.577 Epub 2015 Dec 18.
 7. Moretto P, Wood L, Emmenegger U, et al. Management of small cell 
carcinoma of the bladder: consensus guidelines from the Canadian Asso-
ciation of Genitourinary Medical Oncologists (CAGMO). Can Urol Assoc J. 
2013;7:E44–56.
 8. Celik O, Ekin G, Ipekci T, et al. Diagnosis and treatment in primary 
bladder small cell carcinoma: literature review. Arch Ital Urol Androl. 
2016;88(1):52–5.
 9. Mak RH, Hunt D, Shipley WU, et al. Long-term outcomes in patients 
with muscle-invasive bladder cancer after selective bladder-preserving 
combined-modality therapy: a pooled analysis of Radiation Therapy 
Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin 
Oncol. 2014;32:3801–9.
 10. Siefker-Radtke AO, Dinney CP, Abrahams NA, et al. Evidence supporting 
preoperative chemotherapy for small cell carcinoma of the bladder: 
a retrospective review of the MD Anderson cancer experience. J Urol. 
2004;172(2):481–4.
 11. Siefker-Radtke AO, Kamat AM, Grossman HB, et al. Phase II clinical trial of 
neoadjuvant alternating doublet chemotherapy with ifosfamide/doxoru-
bicin and etoposide/cisplatin in small-cell urothelial cancer. J Clin Oncol. 
2009;27(16):2592–7.
 12. Lynch SP, Shen Y, Kamat A, et al. Neoadjuvant chemotherapy in small 
cell urothelial cancer improves pathologic downstaging and long-term 
outcomes: results from a retrospective study at the MD Anderson Cancer 
Center. Eur Urol. 2013;64(2):307–13.
 13. Thota S, Kistangari G, Daw H, et al. A clinical review of small-cell carci-
noma of the urinary bladder. Clin Genitourin Cancer. 2013;11(2):73–7.
 14. Choong NW, Quevedo JF, Kaur JS. Small cell carcinoma of the urinary 
bladder. The Mayo clinic experience. Cancer. 2005;103(6):1172–8.
